HDFC Mutual FundEquity Scheme - Mid Cap Fund13.8 years
The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 76% of rolling 3-year windows.
Fits if · Three-year return is above the category median.
Prefer peers if · Prefer Edelweiss Mid Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.74% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Watch
Peak-to-trough -39.5%. Ask whether you can hold through a similar fall.
Vs category
Pass
76% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Dhruv Muchhal · 3.4 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 37.3% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 40%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
8 Jan 2018 – 20 Nov 2020
Trough 23 Mar 2020 · recovered in 242 days
-39.5%
19 Aug 2015 – 30 Jun 2016
Trough 25 Feb 2016 · recovered in 126 days
-18.9%
15 Jan 2013 – 28 Nov 2013
Trough 28 Aug 2013 · recovered in 92 days
-18.6%
18 Oct 2021 – 16 Aug 2022
Trough 20 Jun 2022 · recovered in 57 days
-17.0%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
77
Vs category
48
Consistency
75
Risk-adjusted
68
Drawdown
1
Mean
54
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 80 holdings · top 10 are 37.3%.
Repo
Unspecified
8.4%
The Federal Bank Ltd
Financial
4.0%
AU Small Finance Bank Ltd
Financial
3.9%
Max Financial Services Ltd
Financial
3.5%
Ipca Laboratories Ltd
Healthcare
3.4%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
30 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
15 Sept 2026
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Edelweiss Mutual Fund
Caveat: Higher volatility
Baroda BNP Paribas Mutual Fund
Caveat: Higher TER · Lower trailing returns
ITI Mutual Fund
Caveat: Higher volatility · Higher TER
Axis Mutual Fund
Caveat: Higher TER
LIC Mutual Fund
Caveat: Higher volatility · Higher TER · Lower trailing returns
HDFC Mutual FundEquity Scheme - Mid Cap Fund13.8 years
The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · The fund beat the category median in 76% of rolling 3-year windows.
Fits if · Three-year return is above the category median.
Prefer peers if · Prefer Edelweiss Mid Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.74% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Watch
Peak-to-trough -39.5%. Ask whether you can hold through a similar fall.
Vs category
Pass
76% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Dhruv Muchhal · 3.4 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 37.3% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 40%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
30 Oct 2026 · -3.0% over 1Y
215.986
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
30 Oct 2026
-9.1%
8 Jan 2018 – 20 Nov 2020
Trough 23 Mar 2020 · recovered in 242 days
-39.5%
19 Aug 2015 – 30 Jun 2016
Trough 25 Feb 2016 · recovered in 126 days
-18.9%
15 Jan 2013 – 28 Nov 2013
Trough 28 Aug 2013 · recovered in 92 days
-18.6%
18 Oct 2021 – 16 Aug 2022
Trough 20 Jun 2022 · recovered in 57 days
-17.0%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
77
Vs category
48
Consistency
75
Risk-adjusted
68
Drawdown
1
Mean
54
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 80 holdings · top 10 are 37.3%.
Repo
Unspecified
8.4%
The Federal Bank Ltd
Financial
4.0%
AU Small Finance Bank Ltd
Financial
3.9%
Max Financial Services Ltd
Financial
3.5%
Ipca Laboratories Ltd
Healthcare
3.4%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
30 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
15 Sept 2026